Nektar Therapeutics Stock (NASDAQ: NKTR) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 32.000 / 2.550M |
Day Range | - - - |
52 Wk Range | 0.413 - 1.870 |
Market Cap | $328.834M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 66 |
Short Interest | 2.17% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Nektar Therapeutics (NASDAQ: NKTR) through any online brokerage.
Other companies in Nektar Therapeutics’s space includes: Atea Pharmaceuticals (NASDAQ:AVIR), Third Harmonic Bio (NASDAQ:THRD), Theravance Biopharma (NASDAQ:TBPH), Zevra Therapeutics (NASDAQ:ZVRA) and Xeris Biopharma Holdings (NASDAQ:XERS).
The latest price target for Nektar Therapeutics (NASDAQ: NKTR) was reported by Jefferies on Wednesday, March 6, 2024. The analyst firm set a price target for 1.00 expecting NKTR to fall to within 12 months (a possible -44.16% downside). 4 analyst firms have reported ratings in the last year.
The stock price for Nektar Therapeutics (NASDAQ: NKTR) is $1.7908 last updated May 10, 2024 at 7:49 PM EDT.
There are no upcoming dividends for Nektar Therapeutics.
Nektar Therapeutics’s Q2 earnings are confirmed for Tuesday, August 6, 2024.
There is no upcoming split for Nektar Therapeutics.
Nektar Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.